Research progress of alogliptin in treatment of type 2 diabetes mellitus
10.3760/cma.j.issn.1000-6699.2014.10.013
- VernacularTitle:阿格列汀在2型糖尿病治疗中的研究进展
- Author:
Yan ZHOU
;
Qiuhe JI
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Dipeptidyl peptidase-4 inhibitors;
Alogliptin
- From:
Chinese Journal of Endocrinology and Metabolism
2014;30(10):868-871
- CountryChina
- Language:Chinese
-
Abstract:
Alogliptin is a novel dipeptide peptidase-4 inhibitor approved for the treatment of type 2 diabetic mellitus.Numerous clinical studies showed that alogliptin alone or in combination with other oral antidiabetic drugs or insulin can substantially control the level of plasma glucose and glycated hemoglobin (HbA1c) in type 2 diabetic patients.12.5 to 25 mg alogliptin alone once daily reduced HbA1c by 0.56％ to 0.59％ ; while combination with other antidiabetic agents resulted additional HbA1c lowering of 0.4％ to 0.8％.Alogliptin was well tolerated,with low incidence of hypoglycemia and no weight gain.Furthermore,alogliptin displayed no extra cardiovascular risk in patients with cardiovascular diseases.
